A patient's time to progression on first-line CDK4/6 inhibitor therapy acts as an informal biomarker. A shorter duration, such as 14 months, is viewed by experts as "not so great" and indicates a degree of underlying endocrine resistance that influences subsequent treatment strategies.

The ELEGANT trial uses a "switch strategy," introducing elicestrin only after 2-5 years of standard therapy. This design pragmatically adapts to the evolving clinical landscape where CDK4/6 inhibitors are now standard initial treatment, ensuring the trial's relevance by testing the drug in a post-CDK4/6 inhibitor setting.

Post-approval, real-world analyses have validated the efficacy of elacestrant seen in the pivotal EMERALD trial. This confirmation shows that the clinically meaningful progression-free survival of 6-8 months is achievable in routine clinical practice, boosting clinician confidence.

The EMBER-3 trial showed combining the oral SERD imlunestrant with the CDK4/6 inhibitor abemaciclib improved progression-free survival regardless of ESR1 mutation status. This challenges the current paradigm of testing for ESR1 to guide SERD monotherapy, as the combination strategy benefits a broader patient population.

Subgroup analysis from the EMERALD trial reveals a key predictive biomarker: patients with ESR1-mutated breast cancer who benefited from first-line endocrine therapy plus a CDK4/6 inhibitor for over 12 months experienced significantly better progression-free survival on second-line elacestrant, indicating retained endocrine sensitivity.

A key clinical insight from trials like EMERALD is that patients who remain on their first-line CDK4/6 inhibitor for at least 12 months are the most likely to benefit from subsequent oral SERD monotherapy. This duration acts as a surrogate for endocrine sensitivity and helps identify ideal candidates for single-agent treatment.

Data from multiple trials (EMERALD, VERITEC-2) reveal that the duration of a patient's response to a prior CDK4/6 inhibitor acts as a key predictive biomarker. Patients who benefited from CDK4/6 inhibitors for longer periods (e.g., >12-18 months) subsequently experienced a significantly greater progression-free survival benefit from oral SERD therapy.

Large real-world databases show elacestrant monotherapy achieves a median time-to-next-treatment of over 8 months. This impressive outcome aligns with the most favorable subgroup from the pivotal EMERALD trial (patients on prior CDK4/6i >12 months), suggesting that clinicians are successfully identifying the ideal candidates for this therapy in routine practice.

A simple clinical biomarker—having received a prior CDK4/6 inhibitor for over 12 months—identifies patients likely to achieve significant progression-free survival (nearly nine months) with single-agent elacestrant. This allows clinicians to select patients for monotherapy without complex genomic profiling.